Heparin Pretreatment Standard in STEMI
STEMI networks use unfractionated heparin (UFH) pretreatment routinely before catheterization. Early infarct-related artery (IRA) patency saves myocardium and lives. Activated clotting time (ACT) guides anticoagulation in PCI settings usually. Doctors wonder if admission ACT predicts TIMI 2-3 flow reliably. This study published in the International Journal of Cardiology tests that hypothesis directly in real-world patients.
Single-Center STEMI Registry Data
Researchers reviewed 898 consecutive STEMI patients from Codi-IAM network in Catalonia, Spain from 2015 to 2023. Every patient received 5000 units UFH within 120 minutes of symptom onset. ACT measured at arterial catheterization precisely. Diagnostic angiography assessed IRA-TIMI flow immediately. Median ACT values compared between TIMI 0-1 and TIMI 2-3 groups.
Small ACT Differences Observed
Median ACT reached 180 seconds with interquartile range 163-200 in TIMI 0-1 flow patients. TIMI 2-3 flow group showed median 185 seconds with interquartile range 168-203. Differences proved statistically significant but clinically modest. Logistic regression with bootstrap identified independent predictors carefully.
Multiple Factors Influence Reperfusion
Higher ACT associated with TIMI 2-3 flow independently alongside diabetes presence. Shorter symptom-to-heparin time helped reperfusion significantly. Absence of hypertension predicted better flow too. Model performance stayed limited despite these associations.
ACT Lacks Predictive Power
Receiver operating characteristic curve showed area under curve of 0.612 for ACT alone. Brier score confirmed modest discrimination overall. ACT cannot guide clinical decisions reliably for IRA patency prediction. Cath lab teams should not adjust therapy based on this measure.
Time Beats Lab Values
Door-to-heparin time matters more than ACT readings in pretreated STEMI. Rapid UFH administration within 120 minutes optimizes reperfusion chances best. Diabetes and hypertension status provide better risk stratification than coagulation tests.
Standardize STEMI Protocols
Fixed 5000-unit UFH bolus works without ACT guidance in networks. Focus on first medical contact to wire times instead. Prehospital ECG and transfer speed drive outcomes more than lab values.
Rethink Anticoagulation Monitoring
ACT serves cath lab PCI dosing better than STEMI reperfusion prediction. Enoxaparin or bivalirudin alternatives deserve comparison trials. Real-world data challenges routine admission ACT measurement utility.
Clinical Bottom Line Clear
Skip ACT for IRA patency prediction in UFH-pretreated STEMI patients. Prioritize rapid reperfusion pathways instead. These findings guide protocol simplification effectively.